NCT00855530 - Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder | Biotech Hunter

Enrollment

527

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

Major Depressive Disorders

Interventions

DRUG

amibegron (SR58611A)

oral administration of 300 mg twice daily

Trial Locations (11)

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Athens

Sanofi-Aventis Administrative Office, Causeway Bay

Sanofi-Aventis Administrative Office, Casablanca

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Singapore

Sanofi-Aventis Administrative Office, Midrand

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Taipei

Sanofi-Aventis Administrative Office, Mégrine